Teva Pharmaceutical Industries Ltd. will try to win fast European Union approval for its takeover of Allergan’s generics unit by making concessions to regulators, according to “Bloomberg” reports citing” a person familiar with the matter.
READ MORE: TEVA
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
In a letter to the Federal Trade Commission (FTC), The American Antitrust Institute (AAI), a non-profit organization, outlined the competitive concerns raised by the proposed merger of generic pharmaceutical makers More…
The underwriters for Teva Pharmaceutical Industries’ share offering last month have exercised their over-allotment option to purchase additional shares worth $658 million. Following the exercising of these More…
Teva Pharmaceutical Industries Ltd has announced today two offerings totaling approximately $6.75 billion of ordinary and preferred shares to fund its takeover of Allergan Plc’s generic-drug business More…
Teva Pharmaceutical Industries Ltd. and UK-based Heptares Therapeutics, a subsidiary of Tokyo-based Sosei Group have announced a licensing of its migraine treatment candidates. Under the agreement Teva More…
One of the side aspects of the pending Pfizer (PFE)-Allergan (AGN) deal, is that Pfizer will end up owning a 10 percent share in Israel-based Teva Pharmaceutical Industries Ltd. (TEVA) In July, Teva acquired More…
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) is acquiring Rimsa, an independent pharmaceutical company in Mexico with a portfolio of products and patents in Latin America and Europe in More…
